PCV82 COMMUNICATING COST-EFFECTIVENSS RATIOS TO DECISION MAKERS—THE CASE OF SWEDISH NATIONAL GUIDELINES FOR HEART DISEASES  by Eckard, N et al.
A356 13th Euro Abstracts
ivabradine strategy is cost-effective in both approaches in all cases at a willingness to 
pay threshold of c22,000/QALY. CONCLUSIONS: In an Austrian setting, ivabradine 
is a cost-effective treatment in stable angina patients with resting HR > 70 bpm.
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OBJECTIVES: Atrial ﬁ brillation (AF) contributes for stroke, sudden death, heart 
failure, markedly reduced exercise capacity and degraded quality of life. Therefore, 
an effective treatment of AF is expected to reduce cardiovascular (CV) events and their 
costs. In 2010, dronedarone has been approved by Korean FDA for risk reduction of 
CV hospitalization in patients who are in sinus rhythm or who will be cardioverted 
with relevant conditions. The purpose of this study is to evaluate the cost-effectiveness 
of dronedarone compared with amiodarone in Korea. METHODS: We used the 
Markov simulation model for AF patients consisting with health states for AF treat-
ment, off-AF treatment, symptomatic AF recurrences, stroke, acute coronary syn-
dromes, congestive heart failure and death. Transitional probability was obtained 
from ATHENA trial and published literatures. Patient baseline, drug cost, initiation 
and monitoring cost of AF treatment, disease state cost and adverse event cost were 
obtained from national insurance claim database. The effectiveness of amiodarone vs. 
dronedarone was drawn from results of mixed treatment comparison. Discount rate 
for cost and effectiveness were applied as 5%. From the societal perspectives, we 
evaluated cost for life-year gained (LYG) and quality adjusted life-years (QALYs) until 
patients become 100 years old. Subgroup analysis and sensitivity analysis was per-
formed to deal with uncertainty. RESULTS: In the base-case analysis, the incremental 
cost-effectiveness ratio (ICER) of dronedarone versus Amiodarone was approximately 
c2344/LYG (KRW 3.75 million, 1 Euro = 1600 KRW). Results were robust across 
subgroups. The ranges of ICER in the sensitivity analysis were from around c1875 ~ 
c3750/LYG (KRW 3 to 6 million/LYG). Fifty percent of simulations in probabilistic 
sensitivity analysis fall below a willingness-to-pay of about c3750 per QALYs (KRW 
6 million per QALYs). CONCLUSIONS: These results showed that dronedarone is 
to be cost-effective vs. amiodarone for AF patients in Korea.
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OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing 
the risk of cardiovascular disease (CVD). Amlodipine besylate, a calcium channel 
blocker, has been shown to be an effective antihypertensive agent. The objective of 
this study was to evaluate the cost-effectiveness of antihypertensive therapy with 
amlodipine besylate for the prevention of CVD in Korea from a health care perspective 
over a lifetime. METHODS: To estimate long-term cost and effects, a Markov model 
consisting of nine health states was constructed: Healthy with hypertension, Angina, 
Myocardial Infarction (MI), Post-MI, Stroke, Post-stroke, CHD death, CVD death, 
non-CVD cause death. One health state to another can occur with a certain probability 
at yearly intervals. The incidence of CVD was obtained from published local sources, 
whereas the risk reductions associated with antihypertensive therapy were taken from 
the medical literature, selected studies randomly assigned amlodipine besylate or 
placebo and followed up for at least 1 year. Utility values for CVD and costs of 
amlodipine besylate were drawn from published literature based on 2005 Korea 
National Health and Nutritional Examination Survey (KNHANES) data, and Korean 
pharmaceutical pricing lists, respectively. Costs for CVD were found in published 
cost-of-illness studies based on local hospital charge data. Patient outcomes were 
modeled for 45 years, and incremental cost-effectiveness ratios were calculated for 
amlodipine besylate compared with placebo. RESULTS: For a 55-year-old patient 
with hypertension, the incremental cost of amlodipine besylate compared with placebo 
was 3,213,660 Korean won (KW) per patient, although the incremental effectiveness 
of amlodipine besylate was 0.210 quality-adjusted life-years (QALYs) gained per 
patient. Therefore, the incremental cost-effectiveness ratios associated with amlodipine 
besylate were 15,288,941 KW/QALY, compared to no treatment. Sensitivity analyses 
indicated these results to be robust. CONCLUSIONS: The results from the model 
indicate that amlodipine besylate provides a cost-effective antihypertensive treatment 
strategy for the prevention of CVD in Korea.
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OBJECTIVES: The currently recommended standard treatment of the venous throm-
boembolism (VTE) are the oral anticoagulants (OA) in the majority of patients and 
the low-molecular-weight heparins (LMWH) in the selected subpopulations. The 
titration of the OA doses is difﬁ cult and often ineffective. The goal of this research 
was to compare the OA and the LMWH in the VTE treatment in terms of effectiveness, 
safety and cost-effectiveness. METHODS: The systematic review of the scientiﬁ c lit-
erature comparing the VTE treatment with OA and LMWH was performed. Among 
others, the resources of the Cochrane Library, the MEDLINE, the Embase and the 
Biomed Central were searched. The metaanalysis of the reported treatment outcomes 
was performed using the RevMan5® software. The cost analysis and the cost-effec-
tiveness analysis were performed. The data on the costs of treatment of the VTE in 
Poland were collected through the retrospective review of patient records obtained 
from the three hospitals and the anticoagulation clinic in the Krakow area, the phar-
maceutical reimbursement databases and the public payer’s charge tariffs for the 
medical services. The modeling (decision tree) was performed using the TreeAge-
Pro2009® software. RESULTS: The most important differences between the OA and 
the LMWH were related to the better prevention of the VTE incidence and the better 
prevention of the small bleedings. With respect to none of the assessed outcomes the 
OA were better than the LMWH. Within a six month treatment period the Incremental 
Cost-Effectiveness Ratio of avoiding the complication incidents was 49,865 zlotys 
(c12,242) from the payer perspective and 3,609 zlotys (c887) from the patient perspec-
tive. CONCLUSIONS: The LMWH offer the better effectiveness and safety than the 
OA but their cost-effectiveness is still limited by the relatively high prices of the 
LMWH.
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OBJECTIVES: Despite the continuing interest in health economic research, we could 
ﬁ nd no comprehensive and accessible data set on costs and effects, useful as practical 
information for decision makers who must allocate scarce resources within the car-
diovascular ﬁ eld. The objective of this study was to present the cost-effectiveness 
league table, used in the Swedish national guidelines for heart disease and highlight 
issues of importance when communicating and interpreting cost-effectiveness evidence 
to decision makers. METHODS: A unique systematic literature search for the treat-
ment of heart diseases was conducted. We then compiled all available cost-effective-
ness ratios for different heart conditions and treatment strategies, in a so called league 
table. All cost-effectiveness results were expressed as a cost per quality adjusted life-
years (QALY) or life-year gained. The league table was broken down to illustrate how 
health economic results may be communicated and made accessible to decision 
makers. We have highlighted methodological issues when interpreting cost-effective-
ness league tables by using implantable cardioverter deﬁ brillators (ICDs) as an 
example. RESULTS: More than 200 cost-effectiveness ratios were found and compiled 
in the league table ranging from dominant to c950,000 per QALY. Using ICD as an 
example we identiﬁ ed various problems when interpreting league table results. The 
results are context speciﬁ c, time dependant, comparator dependent, often based on 
point-estimates giving a false sense of precision. CONCLUSIONS: League tables 
provide a means of presenting cost-effectiveness evidence aiding decision makers with 
valid information within a limited space. We have given examples and presented ways 
of communicating cost-effectiveness results for e.g. target groups, focusing on how 
information included in a cost-effectiveness league table may be interpreted and 
conveyed and used as a tool in the decision-making process.
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OBJECTIVES: The UK’s National Institute for Health and Clinical Excellence (NICE) 
and the Jordan ofﬁ ce of the Medicines Transparency Alliance embarked on a pilot 
project to design an evidence-based guideline for cost-effective pharmacological treat-
ment of essential hypertension in Jordan. The project’s objectives were to directly 
address a major health problem for Jordan by producing a guideline; and to delineate 
the strengths and weaknesses of Jordan’s health care process to allow similar future 
efforts to be planned more efﬁ ciently. METHODS: The pilot spanned a period of 
approximately 8 months. Activities were overseen by local technical and guideline 
development teams, as well as experts from NICE. NICE’s hypertension guidelines 
and economic model were used as a starting point. Parameters in the economic model 
were adjusted according to input and feedback from local experts with regards to 
Jordanian physician and patient practices, resource costs, and quality of life estimates. 
The results of the economic model were integrated with the updated available clinical 
trial literature. RESULTS: The outputs of the economic model were used to inform 
recommendations, in the form of a clinical algorithm. a report of the process and the 
strengths and weaknesses observed was developed, and recommendations for improve-
ments made. CONCLUSIONS: The pilot represented the start of what is intended to 
be a health care process change for the country of Jordan. Issues emerged which can 
inform strategies to ensure a more cohesive and comprehensive health care approach 
